Is FRUZAQLA approved regardless of mutation status?

FRUZAQLA is a kinase inhibitor of vascular endothelial growth factor receptors (VEGFRs) for adult patients with previously treated mCRC, regardless of mutation status.

For adult patients who have received oxaliplatin- and irinotecan-based regimens

Reimagine Survival in 3L+ mCRC With FRUZAQLA®

Q: What is the approved indication for FRUZAQLA?

FRUZAQLA (fruquintinib) is indicated for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

FRUZAQLA (fruquintinib) delivers targeted, noncytotoxic therapy through convenient, once-daily oral dosing.^1,2

FRUZAQLA + BSC delivered a significant overall survival benefit vs placebo + BSC in FRESCO, extending median OS by 2.7 months (9.3 vs 6.6 months); HR=0.65 (95% CI: 0.51-0.83); P<0.001.²

Dive into the data

What is FRUZAQLA (fruquintinib)?

FRUZAQLA (fruquintinib) is indicated and approved for the treatment of adult patients with mCRC, also known as stage 4 colorectal cancer, who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.¹

FRUZAQLA could redefine what survival looks like for your previously treated patients with mCRC.

Supported by 2 pivotal trials, FRUZAQLA provides:

CONVENIENCE of once-daily oral dosing¹
CONFIDENCE in targeted VEGF inhibition^1,3,4
REAL-WORLD EXPERIENCE established through use in 10,000+ patients treated since US FDA approval in November 2023.⁵

NCCN Category 2A*. National Comprehensive Cancer Network® (NCCN®) recommends fruquintinib (FRUZAQLA) as a potential treatment option for patients with mCRC post exposure to oxaliplatin and irinotecan-based regimens, regardless of mutation status.

^aCoverage relevant to your patients may vary and is subject to change without notice. Status is representative of the coverage for the majority of members covered under each plan. This information is not intended to give advice or promise coverage or payment. Contact the plan for more information about current coverage, restrictions, or requirements that may apply.

^*Category 2A is based upon lower-level evidence, meaning there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.^6,7

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

See recommended sequencing

Mechanism of action

Learn how FRUZAQLA works.

Review the mechanism of action

Bottle of 5 mg FRUZAQLA® (fruquintinib) capsules.

Convenient, oral dosing

Discover simple, once-daily dosing with FRUZAQLA.

Learn about dosing

FRUZAQLA patient profiles

Learn about the types of patients who may benefit from treatment with FRUZAQLA.

Review patient profiles

Ordering FRUZAQLA

Find information on how to order FRUZAQLA for your patients, including distribution and access details.

Start your order

Patient needs in perspective

Learn more about the evolving needs of patients with metastatic colorectal cancer and how FRUZAQLA may address them.

Explore patient needs

3L+= third-line plus; BSC=best supportive care; EGFR=epidermal growth factor receptor; mCRC=metastatic colorectal cancer; OS=overall survival; RAS=rat sarcoma; VEGF=vascular endothelial growth factor.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypertension occurred in 49% of 911 patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity of hypertension.

Hemorrhagic Events including serious, fatal events can occur with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced gastrointestinal hemorrhage, including 1% with a Grade ≥3 event and 2 patients with fatal hemorrhages. Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants.

Infections. FRUZAQLA can increase the risk of infections, including fatal infections. In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%). Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.

Gastrointestinal Perforation occurred in patients treated with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 1.3% experienced a Grade ≥3 gastrointestinal perforation, including one fatal event. Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.

Hepatotoxicity. FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade ≥3 events in 5%, and fatal events in 0.2% of patients. Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests.

Proteinuria. FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade ≥3 events. Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria ≥2g/24 hours, withhold FRUZAQLA until improvement to ≤Grade 1 proteinuria and resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome.

Palmar-Plantar Erythrodysesthesia (PPE) occurred in 35% of 911 patients treated with FRUZAQLA, including 8% with Grade 3 events. Based on severity of PPE, withhold FRUZAQLA and then resume at the same or reduced dose.

Posterior Reversible Encephalopathy Syndrome (PRES), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 911 patients treated with FRUZAQLA. Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.

Impaired Wound Healing. In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence. Do not administer FRUZAQLA for at least 2 weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events. In 911 patients with mCRC treated with FRUZAQLA, 0.8% of patients experienced an arterial thromboembolic event. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism, discontinue FRUZAQLA.

Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF). FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.

Embryo-Fetal Toxicity. Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥20%) following treatment with FRUZAQLA included hypertension, palmar-plantar erythrodysesthesia (hand-foot skin reactions), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.

DRUG INTERACTIONS

Avoid concomitant administration of FRUZAQLA with strong or moderate CYP3A inducers.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.

Females and Males of Reproductive Potential

Pregnancy Testing: Verify pregnancy status of females of reproductive potential prior to initiating FRUZAQLA.
Contraception: Females of childbearing potential and males with female partners of childbearing potential should use effective contraception during treatment and for 2 weeks after the last dose of FRUZAQLA.
Infertility: Advise females of reproductive potential that FRUZAQLA may cause post-implantation loss.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see FRUZAQLA (fruquintinib) full Prescribing Information.

Reimagine Survival in 3L+ mCRC With FRUZAQLA®

What is FRUZAQLA (fruquintinib)?

Mechanism of action

Convenient, oral dosing

FRUZAQLA patient profiles

Ordering FRUZAQLA

Patient needs in perspective

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION